TRK Inhibition with Entrectinib in Metastatic Salivary Secretory Carcinoma (SC): A Case Report

NTRK gene fusions are rare oncogenic driver mutations that can be found in a broad range of neoplasms. In secretory carcinoma (SC), <i>ETV6-NTRK3</i> gene fusion is seen in a majority of the cases and represents a druggable target for patients with advanced disease in the absence of a currently acce...

Deskribapen osoa

Xehetasun bibliografikoak

Egile Nagusiak:	Matthew S. Ernst, John T. Lysack, Martin D. Hyrcza, Shamir P. Chandarana, Desiree Hao
Formatua:	Artigo
Hizkuntza:	Inglês
Argitaratua:	MDPI AG 2022-05-01
Saila:	Current Oncology
Gaiak:	secretory carcinoma NTRK entrectinib larotrectinib targeted therapy molecular testing
Sarrera elektronikoa:	https://www.mdpi.com/1718-7729/29/6/314
Etiketak:	Etiketa erantsi Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!